GENELUX Corp
GNLXNasdaq
$2.87
↑ +1.8%Jul 17 close · end-of-day
Price
1Y↓ -6.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$126.7M
Enterprise Value
$100.5M
P/E
—
P/S
—
P/B
5.5
EV/EBITDA
—
PEG
—
FCF Yield
-22.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$33.6M
Free Cash Flow (TTM)
-$27.9M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-146.5%
ROIC
—
Debt / Equity
—
Net Cash
$26.2M
Return 1Y
-15.6%
Company profile
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our principal executive offices are located at 2625 Townsgate Road, Suite 230, Westlake Village, California.
- CEO
- Thomas Zindrick
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- California
- Website
- www.genelux.com
Management & directors
- Cappello JosephChief Technical Officer
- Groen EricGeneral Counsel
- Pulisic MatthewChief Financial Officer
- Yu TonySVP, Clinical Development
- Zindrick ThomasPresident and CEO
- Smalling RalphHead of Regulatory
Roles derived from SEC Form 4 filings.
Earnings
GNLX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.20↓ -4.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $11.1M | $170,000.00 | $8,000.00 | $8,000.00 |
| Gross profit | — | — | — | — |
| Operating income | -$3.0M | -$24.2M | -$31.7M | -$33.2M |
| Net income | -$5.2M | -$28.3M | -$29.9M | -$32.1M |
| Diluted EPS | -$0.57 | -$1.16 | -$0.95 | -$0.86 |
| Operating cash flow | -$3.6M | -$20.3M | -$21.2M | -$25.3M |
| Free cash flow | -$3.6M | -$21.3M | -$21.6M | -$26.4M |
| Gross margin | — | — | — | — |
| Operating margin | -27.2% | -14214.7% | -396200.0% | -415175.0% |
| Net margin | -47.0% | -16645.3% | -373362.5% | -401812.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$6.9M | -$6.9M | -$9.7M | -$7.8M | -$7.8M | -$8.2M | -$9.4M | -$9.2M |
| Net income | -$6.6M | -$6.5M | -$9.0M | -$7.5M | -$7.5M | -$8.0M | -$9.2M | -$8.9M |
| Diluted EPS | -$0.22 | -$0.19 | -$0.25 | -$0.21 | -$0.20 | -$0.21 | -$0.24 | -$0.20 |
| Operating cash flow | -$6.8M | -$5.7M | -$4.3M | -$5.4M | -$7.1M | -$6.6M | -$6.2M | -$6.1M |
| Free cash flow | -$7.1M | -$5.8M | -$4.4M | -$5.5M | -$7.2M | -$7.1M | -$6.6M | -$7.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Smither John W | Sale | 12,000 | $2.91 | $34,898.40 | filing |
| 2026-06-16 | Pulisic Matthew· Chief Financial Officer | Award | 278,906 | $0.00 | $0.00 | filing |
| 2026-06-16 | Groen Eric· General Counsel | Award | 233,957 | $0.00 | $0.00 | filing |
| 2026-06-16 | Cappello Joseph· Chief Technical Officer | Award | 174,841 | $0.00 | $0.00 | filing |
| 2026-06-16 | Tyree James L | Award | 28,409 | $0.00 | $0.00 | filing |
| 2026-06-16 | Zindrick Thomas· President and CEO | Award | 730,601 | $0.00 | $0.00 | filing |
| 2026-06-16 | Thomas John | Award | 28,409 | $0.00 | $0.00 | filing |
| 2026-06-16 | Mirabelli Mary | Award | 28,409 | $0.00 | $0.00 | filing |
| 2026-06-16 | Yu Tony· Chief Scientific Officer | Award | 119,318 | $0.00 | $0.00 | filing |
| 2026-06-16 | Smither John W | Award | 28,409 | $0.00 | $0.00 | filing |
| 2026-06-03 | Smalling Ralph· Head of Regulatory | Sale | 192 | $2.93 | $562.56 | filing |
| 2026-06-01 | Thomas John | Sale | 10,000 | $2.98 | $29,801.00 | filing |
| 2026-05-11 | Zindrick Thomas· President and CEO | Sale | 2,798 | $2.94 | $8,225.56 | filing |
| 2026-05-11 | Cappello Joseph· Chief Technical Officer | Sale | 605 | $2.97 | $1,799.39 | filing |
| 2026-05-11 | Yu Tony· Chief Scientific Officer | Sale | 605 | $2.97 | $1,798.42 | filing |
| 2026-05-11 | Smalling Ralph· Head of Regulatory | Sale | 270 | $2.98 | $804.49 | filing |
| 2026-03-25 | Smalling Ralph· Head of Regulatory | Sale | 240 | $2.51 | $602.40 | filing |
| 2026-03-24 | Zindrick Thomas· President and CEO | Sale | 3,582 | $2.42 | $8,668.44 | filing |
| 2026-03-24 | Cappello Joseph· Chief Technical Officer | Sale | 906 | $2.42 | $2,192.52 | filing |
| 2026-03-24 | Yu Tony· SVP, Clinical Development | Sale | 906 | $2.42 | $2,192.52 | filing |
| 2026-03-24 | Smalling Ralph· Head of Regulatory | Sale | 345 | $2.42 | $834.90 | filing |
| 2026-03-02 | Thomas John | Sale | 10,000 | $2.90 | $28,957.00 | filing |
| 2025-12-05 | Smalling Ralph· Head of Regulatory | Sale | 165 | $4.69 | $773.85 | filing |
| 2025-12-01 | Thomas John | Sale | 10,000 | $5.00 | $50,008.00 | filing |
| 2025-11-17 | Zindrick Thomas· President and CEO | Sale | 4,509 | $5.37 | $24,210.62 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.